)
Jedd Wolchok, MD, PhD
Meyer Director
The Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine
Dr. Jedd D. Wolchok is a pioneering figure in cancer immunotherapy, renowned for his instrumental role in the development and approval of groundbreaking treatments for melanoma. His leadership in clinical trials led to the FDA approval of ipilimumab, the first checkpoint inhibitor immunotherapy, and the combination of nivolumab and ipilimumab, establishing new standards of care for advanced melanoma patients. Throughout his career, Dr. Wolchok has been at the forefront of translational research, focusing on novel immunotherapeutic agents and the mechanisms of immune response to cancer. His laboratory has significantly contributed to understanding the tumor microenvironment and developing strategies to overcome resistance to immunotherapy. His contributions have been recognized with numerous prestigious awards, including the His work continues to shape the future of cancer treatment, emphasizing the potential of immunotherapy to provide durable control across various cancer types.
Sessions
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}